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D
espite the “3 by 5” initiative [1], 
which aims to treat 3 million 
people with antiretrovirals 
(ARVs) by the end of 2005, access to 
ARVs in resource-poor settings remains 
limited. Moreover, in some ARV-access 
programmes, free ARVs are provided 
only, or preferentially, to patients who 
are ARV naive. 
Treatment restricted to patients who 
are ARV naive was initially the case in 
Uganda, with the free ARVs provided 
by the Multi-Country AIDS Programme 
and the Presidential Emergency Plan 
for AIDS Relief. While in the policy 
documents of both projects it was 
not stated that free ARVs should be 
given preferentially to ARV-naive 
patients, many physicians involved 
in the roll-out of ARVs in Uganda 
felt that this was what these projects 
were recommending. Indeed, the 
Ministry of Health’s “Antiretroviral 
Treatment Policy for Uganda” stated 
that “those who are clinically eligible 
and can afford to pay for ART will be 
encouraged to do so. Those already in 
privately provided and privately paid 
ART should be encouraged to remain 
in this situation. Others who become 
clinically eligible over time and have 
the ability to pay or have a third party 
able to pay in their place or cost share 
with them, should pay full cost for 
ART, whether they avail themselves 
of treatment provided in the public 
or private sector” [2]. These policy 
statements were interpreted by many 
clinicians to mean that patients who 
are already paying for their drugs can 
afford to do so and are not a priority 
for free drugs.
In this essay, we explain the rationale 
for restricting free access to treatment-
naive patients, and then we outline the 




There are four 
principal reasons 





regimens are more 
predictable in ARV-
naive patients [3]. 
Programmes limited 
to this population 
will provide what 
donors most desire: 
good outcomes. 
Secondly, ARV-
naive patients will 
usually respond 
readily to less 
expensive ﬁ  rst-line ARV regimens, 
and only a few will require more 
complex and costly second-line 
ARVs. Thirdly, results of programmes 
are easier to compare, because 
similar ARV regimens are started in 
more homogeneous, comparable 
populations. And ﬁ  nally, it is often 
believed that patients who in the past 
have been able to buy ARVs should 
continue to do so. 
Problems with a Restricted-Access 
Strategy
There are, however, serious problems 
with this strategy of restricted access. 
To start, patients are quick to share 
information, and rumours spread 
fast regarding ways to obtain free 
ARVs. When patients learn that ARVs 
are being given at no cost only to 
treatment-naive patients, they may 
not disclose that they have taken 
ARVs in the past, even to experienced 
counsellors. We discovered such 
patients in our centre when they were 
found to have an undetectable viral 
load or a CD4+ lymphocyte count 
higher than expected, when tested 
prior to starting ARVs. Only when 
confronted about these results did they 
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acknowledge prior ARV experience. 
Such withholding of information 
may result in clinicians choosing 
inappropriate ARV regimens, thereby 
placing patients at risk of adverse 
effects or of development of resistance.
Second, forcing some patients to 
pay for ARVs can have disastrous 
consequences for adherence to long-
term treatment. Our experience 
in Uganda has shown that if ARVs 
are provided for free through an 
international organisation or a clinical 
trial, patients achieve excellent 
adherence. In contrast, if patients or 
their relatives pay for drugs themselves, 
treatment failure and the development 
of resistance is frequently observed [4]. 
A study in Senegal found that user fees 
had a negative effect on adherence 
and were associated with frequent 
interruptions in treatment [5], and 
there have been similar ﬁ  ndings in 
Kenya [6], Botswana [7], Cote d’Ivoire 
[8], and Nigeria [9]. Data from 
West Africa showed that the level of 
adherence in the treated population 
was inversely proportional to the 
amount of co-payment [10]. 
In Uganda, currently about 56,000 
patients are being treated with ARVs, 
and about 52% of these treatment 
regimens are paid for by patients 
or their relatives (E. Namagala 
[Uganda Ministry of Health], personal 
communication). Most of these patients 
are relatively poor and most have had 
life-threatening HIV complications. 
Almost all are struggling with the 
expense. Many in the near future will 
be forced, from lack of resources, to 
either stop their 
ARVs or take them 
irregularly. Patients 
and their families 
are more willing 
to sacriﬁ  ce scarce 
resources to pay 
for ARVs when 
patients are ill, but 
once they achieve 
a better health 
status, additional 
priorities, such as 
school fees, tend to 
take precedence, 
resulting in poor 
adherence. It is, 
therefore, essential 
that free ARVs 
be offered to all 
patients if they are 
to remain well and if development of 
resistance is to be thwarted. 
Third, programmes that offer ARVs 
only to ARV-naive patients may be 
relatively slow to enrol patients. All 
patients beginning ARV therapy for 
the ﬁ  rst time must be carefully selected 
and prepared, and this can take several 
clinic visits, including counselling 
sessions. Moreover, once patients have 
been started on ARVs, they must be 
followed closely for side effects and to 
ensure adherence to the regimen. In 
contrast, patients already taking ARVs 
and known to be adherent to their 
regimen could be enrolled quickly, 
with less effort. 
The Human Rights Dimension
Finally, we also believe that selecting 
only ARV-naive patients for free 
ARVs raises a human rights issue. Can 
treatment be denied to those who 
have somehow found money to initiate 
therapy—often forestalling their 
demise—and who are now struggling to 
pay for ARVs? 
Most of these patients have 
made great sacriﬁ  ces to access 
ARV treatment. They have kept 
appointments at the clinic, and they 
have been adherent to their treatment 
regimen as long as money was found 
to purchase ARVs. In contrast, other 
individuals may have delayed being 
tested for HIV, while continuing risky 
behaviour, and only accepted HIV 
testing because of the promise of free 
ARVs. Many of them have not been 
as ill as those who have managed to 
somehow ﬁ  nd resources to initiate 
treatment. 
Since the increased access to free 
ARVs, a sharp increase in HIV testing 
has been noted at voluntary testing and 
counselling sites in Kampala, Uganda, 
and also in many other countries 
[11]. In Uganda in the Mulago–
Mbarara Teaching Hospitals’ Joint 
AIDS Programme supported by the 
President’s Emergency Plan for AIDS 
Relief, 15,000 patients were tested for 
HIV in the last seven months, and 40% 
of these patients were HIV positive. 
Although these newly diagnosed 
ARV-naive patients who meet the 
biological criteria for ARV treatment 
should be treated, we must be able 
to also prioritise individuals for ARVs 
who are “HIV veterans” and are now 
barely ﬁ  nding money or have already 
exhausted their resources to pay for 
their drugs. 
Today in Uganda, ARVs provided by 
the Multi-Country AIDS Programme, 
the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria, and the 
President’s Emergency Plan for AIDS 
Relief are also used for patients 
that previously paid for the drugs 
themselves. Nevertheless, many patients 
still have not been taken in by these 
free ARV programmes. It is important 
that ARV roll-out projects in other 
countries learn from this experience in 
Uganda.  
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